Scientists Begin First Human Trial of Cellular Reprogramming to Reverse Aging
Nature reported on June 9, 2026, that the first participant has been treated in a landmark clinical trial of cellular reprogramming — an approach that attempts to reverse the biological aging of cells by resetting their epigenetic state. The trial is run by Life Biosciences, a Boston biotech co-founded by Harvard professor David Sinclair. The FDA cleared the company's Investigational New Drug application in January 2026, and the Phase 1 study started enrolling patients in the first quarter of the year. This is the first time a partial epigenetic reprogramming therapy has entered a human being.
What cellular reprogramming actually does
The underlying biology draws on the Nobel Prize-winning discovery by Shinya Yamanaka that introducing a handful of specific genes into an adult cell can push it backward toward an embryonic stem-cell-like state. Life Biosciences uses three of the four original Yamanaka factors — OCT4, SOX2, and KLF4, known together as OSK — delivered via gene therapy directly into the eye. The company excludes c-Myc, the fourth factor, which is associated with uncontrolled cell growth and tumor formation. That design choice is meant to make cells younger without pushing them all the way back to stem cells, preserving their original identity.
The therapy is controlled with doxycycline, a common antibiotic. Patients take a low dose for about eight weeks; when they stop, the gene therapy switches off. The eye is the first target because it is well-contained, injection doses can be very small, and the anatomy limits systemic exposure. The gene therapy is delivered by a single viral vector directly to retinal ganglion cells, the neurons that transmit light signals from the eye to the brain.
Who is being treated and what researchers are watching
The Phase 1 trial is enrolling patients with two conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, sometimes called a stroke of the eye, which can cause sudden vision loss in adults over fifty. Both are age-related diseases that damage retinal ganglion cells — the direct target of the OSK therapy. This phase is primarily a safety study. The protocol tests two doses in up to six glaucoma patients before moving to NAION patients, with multiple visual function measurements taken throughout to look for any hint of efficacy.
The scientific rationale traces back to experiments in Sinclair's lab that restored vision in older mice with damaged optic nerves. That work was followed by non-human primate studies showing controlled gene expression, restored methylation patterns, and improved visual function with no systemic toxicities. The FDA reviewed those results before granting clearance. Whether those findings translate to humans is exactly what this trial is designed to begin answering.
Why this trial matters beyond eye disease
The reprogramming field has attracted significant investment from high-profile backers. Altos Labs launched with $3 billion from investors including Amazon's Jeff Bezos. Retro Biosciences is backed by OpenAI's Sam Altman. New Limit has funding from Coinbase CEO Brian Armstrong. None of them have yet put a reprogramming therapy into a human being. Life Biosciences has now done that.
The current trial will not settle whether aging itself can be reversed. It will establish whether the OSK approach is safe in human tissue and provide early signals about whether the epigenetic reset observed in animal models can replicate in people. YouthBio CEO Yuri Deigin, whose company is developing a separate reprogramming-based Alzheimer's therapy, called the FDA clearance "a strong signal for the broader longevity space that regulators are increasingly willing to evaluate therapies that aim to modify upstream epigenetic drivers of aging, rather than only treating downstream symptoms."
If the Phase 1 data comes back clean, the field opens toward far larger questions: whether the same reset can be applied to the liver, kidney, heart, or brain, where the potential scale of impact would be orders of magnitude greater. The first human data is expected sometime in late 2026 or early 2027, depending on patient recruitment pace and safety monitoring intervals.